Dr Daniel Hollyman

Dr Dan Hollyman is Head of Stem Cell & Immunotherapies, NHS Blood and Transplant, Birmingham. He has a strong track record in providing cell therapy products for clinical use.

Head of Stem Cell & Immunotherapies, NHS Blood and Transplant (NHSBT), Birmingham

Email: daniel.hollyman@nhsbt.nhs.uk

LinkedIn profile

Background and Research focus

As Head of Stem Cell and Immunotherapies, NHSBT Birmingham, Dan is responsible for providing autologous and allogeneic stem cell transplantation services, primarily across the Midlands, but also to other UK and international institutions. He directly manages a staff of ~12 people, focussed on a variety of activities including a range of complex cell manipulations, development of early phase clinical trial products, and management of on-site and satellite cryostorage facilities for human application. Dan’s management duties include maintenance of JACIE (Joint Accreditation Committee of the ISCT and the EBMT) accreditation, HTA (Human Tissue Authority) licensing, and EU GMP compliance, responsibility for budget control and business development, quality management system operation, quality incident reporting, and clinical risk assessment. Dan also arranges third party agreements, service level agreements, and contract manufacturing contracts for testing, collection and storage of cell products. Finally, Dan is responsible for clinical liaison for six hospital sites including Quality Management and Bone Marrow Transplant meetings.

Dan has extensive experience in Stem Cell service provision and immunotherapy development. Having completed a PhD in oncology at UCL, Dan joined the National Blood Service as a Stem Cell Scientist for ~2 years from 2003, where he received a broad training in diverse aspects of stem cell services and provision, including those supporting autologous and allogeneic transplantation programs. He then relocated to the US for 4 years, where he was appointed manager of the Gene Transfer Facility at the Memorial Sloan-Kettering Cancer Center in New York. There he managed a variety of cell product pipelines within a cGMP manufacturing facility, including viral vectors, T cells/CD34+ stem cells, engineered cell products (e.g. antigen-specific T cells, vector engineered CD34+ cells, and artificial antigen presenting cell systems). He also gained valuable experience in development of closed-systems for clinical application. During this time, projects focussing on chimeric antigen receptor-mediated autologous T cell therapies, manufacturing of GMP-grade artificial antigen-presenting cells, antibody-mediated immunotherapies, and lentiviral gene transfer of stem cells for correction of genetic disorders, were particularly successful.


stem cell transplantation ; cell product provision and manipulation; immunotherapy strategies; regulatory compliance for cell therapy; HTA licensing; GMP compliance; JACIE accreditation; regulatory approval for cell therapy and biologics, including MHRA and FDA regulations; clean room and GMP room operation; cryostorage; facility management; early phase clinical trial development; clinical risk assessment.

Other activities

In addition to leading his own research group, Dan is a member of the CIIC Advisory Board; an Associate Scientific Member of the Cellular Therapy Team for the Biomedical Excellence for Safer Transfusion (BEST) collaborative; and an Elected Member for the AABB’s Cell Therapy Standards Co-ordinating Committee. Finally, he is a JACIE inspector for Cell Processing.


Estcourt LJ, Heddle N, Kaufman R, McCullough J, Murphy MF, Slichter S, Wood EM, Stanworth SJ; Biomedical Excellence for Safer Transfusion Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion. 2013 Jul;53(7):1531-43.

Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone Marrow Transplant. 2013 Feb;48(2):243-8.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski  M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Nov 3;118(18):4817-28.

Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009 Feb-Mar;32(2):169-80.

Quintás-Cardama A, Yeh RK, Hollyman D, Stefanski J, Taylor C, Nikhamin Y, Imperato G, Sadelain M, Rivière I, Brentjens RJ. Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther. 2007 Dec;18(12):1253-60.

Guttridge MG, Belfield H, Hollyman D, Lankester A, Watt SM. An internal positive control for the enumeration of CD45(+) and CD34(+) cells by flow cytometry allows monitoring of reagent and operator performance. Cytotherapy. 2007;9(3):275-82.

Sharp TV, Wang HW, Koumi A, Hollyman D, Endo Y, Ye H, Du MQ, Boshoff C. K15 protein of Kaposi’s sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol. 2002 Jan;76(2):802-16.